

GEORGIA Diabetes Data & Forecasts

State Total Population Forecasts	2015	2020	2025	2030
Entire Population	10,230,600	10,843,800	11,438,600	12,017,800
Prediabetes	2,800,300	3,066,000	3,331,000	3,504,300
Diagnosed diabetes	852,000	1,069,600	1,268,500	1,439,100
Undiagnosed diabetes	288,400	343,900	386,900	415,900
Total with diabetes (diagnosed and undiagnosed)	1,140,400	1,413,500	1,655,500	1,855,000
Complications:				
Visual impairment	139,700	170,300	196,000	215,900
Renal failure	2,030	2,460	2,820	3,080
Leg amputations	1,760	2,030	2,220	2,320
Annual deaths attributable to diabetes	9,180	11,000	12,390	13,310
Total annual cost (2015 dollars)	\$11.7 B	\$14.5 B	\$16.9 B	\$18.9 B
Annual medical costs	\$8.7 B	\$10.7 B	\$12.5 B	\$13.9 B
Annual nonmedical costs	\$3.0 B	\$3.8 B	\$4.4 B	\$5.0 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	1,187,600	1,409,900	1,659,700	1,907,800
Prediabetes	605,700	719,100	846,400	973,000
Diagnosed diabetes	224,500	266,500	313,700	360,600
Undiagnosed diabetes	83,100	98,700	116,200	133,500
Total with diabetes (diagnosed and undiagnosed)	307,600	365,200	429,900	494,100
Complications:				
Visual impairment	42,000	48,600	55,700	62,400
Renal failure	690	790	900	1,000
Leg amputations	520	570	620	660
Annual deaths attributable to diabetes	6,330	7,370	8,050	8,380
Total annual cost (2015 dollars)	\$3.9 B	\$4.7 B	\$5.5 B	\$6.3 B
Annual medical costs	\$3.7 B	\$4.4 B	\$5.2 B	\$5.9 B
Annual nonmedical costs	\$0.2 B	\$0.3 B	\$0.3 B	\$0.4 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.